Regeneron Pharmaceuticals

from Wikipedia, the free encyclopedia
Regeneron Pharmaceuticals

logo
legal form Incorporated
ISIN US75886F1075
founding 1988
Seat Tarrytown , United States
management Leonard S. Schleifer, President & CEO
Number of employees 8,100
sales 5,872,000,000 USD
Branch pharmacy
Website www.regeneron.com
As of December 31, 2019

The biotechnology company Regeneron Pharmaceuticals was founded in 1988 and is traded on the NASDAQ stock exchange under the symbol "REGN". Regeneron Pharmaceuticals is a global leader in the manufacture of monoclonal antibodies , some of which Regeneron markets itself, but some of which are also sold under license or in cooperation with other companies, such as Bayer or Sanofi .

Products

Regeneron Pharmaceuticals is a leader in human antibody production and has a significant pipeline of experimental candidates for the treatment of cancer, rheumatoid arthritis and hypercholesterolemia , for example . The strategic cooperation with Sanofi enables the company to make a long-term forecast of the financing.

Rilonacept (tradename Arcalyst) is an interleukin-1 inhibitor ; H. an anti-inflammatory medicine used to treat the rare hereditary disorder cryopyrin-associated periodic syndrome (CAPS). It was Regeneron's first drug and was approved by the Food and Drug Administration (FDA) in the US in 2008 .

Aflibercept is a recombinant growth factor inhibitor that - under the trade name Eylea - is used to treat age-related macular degeneration (AMD) . In Germany, Eylea is marketed by Bayer Healthcare Pharmaceuticals. Under the trade name Zaltrap, the same substance is used for the treatment of metastatic colorectal cancer. (mCRC) . Eylea is the company's main product.

pipeline

literature

Individual evidence

  1. ^ Regeneron Pharmaceuticals: Investor FAQs . 2014. Retrieved March 30, 2014.
  2. ^ Regeneron Pharmaceuticals: Company - Management . 2014. Retrieved March 30, 2014.
  3. ↑ About Regeneron Pharmaceuticals: Innovative Biotechnology. In: Company information. 2020, accessed on February 12, 2020 .
  4. ↑ a b Regeneron: 2017 Form 10-K Report. (PDF) Retrieved March 17, 2018 (English).
  5. ↑ a b c Regeneron Pharmaceuticals: Pipeline . 2014. Retrieved March 30, 2014.
  6. ^ Regeneron Pharmaceuticals: Company . 2014. Retrieved March 30, 2014.
  7. ↑ www.regeneron.com/ARCALYST , Rilonacept on the manufacturer's website (English), accessed on March 30, 2014.
  8. ↑ New medicines Eylea (Aflibercept) (PDF; 132 kB) Information from the Medicines Commission of the German Medical Association (AkdÄ), as of February 28, 2013
  9. ↑ New on the market: Aflibercept in Macular Degeneration DAZ from January 16, 2013, accessed on March 30, 2013.
  10. ↑ New drugs Zaltrap (Aflibercept) (PDF; 852 kB) Information from the drug commission of the German medical profession (AkdÄ), as of May 22, 2013.